PDCD1LG2 and prostate carcinoma: Zhao et al. [8] demonstrated the association between high expression levels of programmed cell death 1 ligand 2 (PD‐L2) and poor outcomes in prostate cancer patients, as well as its link with postoperative radiation therapy.